EX-99.B 3 y41577ex99-b.txt SUPPLEMENTAL INFORMATION 1 EXHIBIT 99(b) MERCK & CO., INC. PRODUCT SALES DETAIL
3Q `00 vs. 3Q `99 TOTAL TOTAL U.S. U.S. Foreign Foreign PRODUCT % CHG $ % CHG $ % CHG $ VIOXX N/M $615 N/M $495 N/M $120 VASOTEC / VASERETIC -5% 460 21% 205 -19% 255 PRINIVIL / PRINZIDE 34% 295 36% 265 20% 30 COZAAR / HYZAAR 16% 405 6% 175 24% 230 MEVACOR 17% 135 29% 110 -17% 25 ZOCOR 18% 1,360 27% 905 3% 455 AGGRASTAT 75% 35 67% 25 100% 10 SINGULAIR 81% 235 90% 190 50% 45 MAXALT 80% 45 75% 35 100% 10 PROPECIA 11% 50 25% 25 0% 25 PROSCAR 9% 120 30% 65 -8% 55 PRIMAXIN 0% 140 -11% 40 5% 100 PEPCID -16% 190 -13% 175 -40% 15 FOSAMAX 29% 360 33% 260 18% 100 CRIXIVAN/STOCRIN -18% 140 -23% 50 -14% 90 TIMOPTIC/TIMOPTIC XE -14% 60 -40% 15 0% 45 TRUSOPT/COSOPT 13% 90 13% 45 13% 45 HEPATITIS VACCINES 31% 105 36% 95 N/M 10 VIRAL VACCINES 0% 155 4% 145 N/M 10 OTHER VACCINES N/M 20 N/M 10 N/M 10
NOTE: Product sales rounded to the nearest $5 million. N / M - Not Meaningful 2 EXHIBIT 99(b) MERCK & CO., INC. PRODUCT SALES DETAIL
9 MONTHS YTD 2000 OVER 1999 TOTAL TOTAL U.S. U.S. Foreign Foreign PRODUCT % CHG $ % CHG $ % CHG $ VIOXX N/M $1,460 N/M $1,175 N/M $285 VASOTEC / VASERETIC -15% 1,460 -12% 640 -17% 820 PRINIVIL / PRINZIDE 34% 835 36% 750 13% 85 COZAAR / HYZAAR 22% 1,185 15% 505 27% 680 MEVACOR -15% 395 -15% 320 -17% 75 ZOCOR 19% 3,820 31% 2,440 2% 1,380 AGGRASTAT 82% 100 67% 75 N/M 25 SINGULAIR 86% 615 92% 480 69% 135 MAXALT 108% 135 110% 105 100% 30 PROPECIA 11% 150 0% 70 23% 80 PROSCAR 6% 345 18% 165 -3% 180 PRIMAXIN 7% 450 4% 130 8% 320 PEPCID -10% 610 -8% 555 -21% 55 FOSAMAX 27% 960 33% 670 16% 290 CRIXIVAN/STOCRIN -17% 410 -23% 155 -14% 255 TIMOPTIC/TIMOPTIC XE -10% 190 -23% 50 -3% 140 TRUSOPT/COSOPT 15% 265 14% 125 17% 140 HEPATITIS VACCINES 20% 270 23% 245 0% 25 VIRAL VACCINES 7% 405 7% 380 N/M 25 OTHER VACCINES N/M 50 N/M 30 N/M 20
NOTE: In-line product sales rounded to the nearest $5 million. N / M - Not Meaningful 3 EXHIBIT 99(b) MERCK & CO., INC. THIRD QUARTER
3Q `00 3Q `99 % CHG. TOTAL SALES $ 10,567.5 $ 8,195.7 29% ---------- --------- TOTAL COSTS, EXPENSES, & OTHER $ 7,925.8 $ 5,961.0 ---------- --------- Materials & Production 5,952.5 4,365.9 Marketing & Administrative 1,512.8 1,272.7 Research & Development 609.8 516.0 Acquired Research - 51.1 Equity Income From Affiliates (219.4) (227.1) Other (Income)/Expense, Net 70.1 (17.6) PRE-TAX INCOME $ 2,641.7 $ 2,234.7 TAXES $ 805.7 $ 695.1 TAX RATE 30.5% 31.1% NET INCOME $ 1,836.0 $ 1,539.6 19% EPS - ASSUMING DILUTION $0.78 $0.64 22% AVG. # SHARES - ASSUMING DILUTION 2,342.9 2,394.4
3Q `00 % CHG. VOL PX FX TOTAL SALES $10,570 29% 25 4 0 ------- --- -- -- -- Total U.S. and Foreign Sales 5,170 18% 21 -2 -1 ------- --- -- -- -- U.S. 3,345 23% 25 -2 0 Foreign 1,825 9% 13 -2 -2 Other Medco Sales 5,400 42%
4 EXHIBIT 99(b) MERCK & CO., INC. NINE MONTHS YEAR TO DATE
2000 1999 % CHG. TOTAL SALES $ 28,895.9 $ 23,750.6 22% ------------ ------------ --- TOTAL COSTS, EXPENSES, & OTHER $ 21,582.9 $ 17,342.5 ------------ ------------ Materials & Production 15,872.9 12,890.2 Marketing & Administrative 4,393.5 3,611.3 Research & Development 1,681.5 1,440.5 Acquired Research -- 51.1 Equity Income From Affiliates (619.5) (581.5) Other (Income)/Expense, Net 254.5 (69.1) PRE-TAX INCOME $ 7,313.0 $ 6,408.1 TAXES $ 2,255.7 $ 2,090.8 TAX RATE 30.8% 32.6% NET INCOME $ 5,057.3 $ 4,317.3 17% EPS - ASSUMING DILUTION $2.15 $1.79 20% AVG. # SHARES - ASSUMING DILUTION 2,351.6 2,410.1
9 mos `00 % CHG. VOL PX FX TOTAL SALES $28,895 22% 18 4 0 ------- --- -- -- -- Total U.S. and Foreign Sales 14,820 18% 21 -2 -1 ------- --- -- -- -- U.S. 9,430 24% 26 -2 0 Foreign 5,390 8% 11 -1 -2 Other Medco Sales 14,075 26%
5 EXHIBIT 99 (b) MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES THIRD QUARTER 2000 OTHER (INCOME)/EXPENSE, NET
3Q `00 3Q `99 9 mos '00 9 mos '99 INTEREST INCOME $(124.8) $(95.2) $(326.4) $(264.1) INTEREST EXPENSE 121.8 79.0 355.1 219.3 EXCHANGE (GAINS)/LOSSES (14.3) (20.9) (31.8) (18.8) MINORITY INTERESTS 74.8 61.8 230.8 168.5 AMORTIZATION OF GOODWILL AND INTANGIBLES 80.8 77.8 238.2 239.0 Other, net (68.2) (120.1) (211.4) (413.0) ------- ------ ------- ------- TOTAL $ 70.1 $(17.6) $ 254.5 $ (69.1)
JOINT VENTURE SALES DETAIL All sales reported here are end-market JV sales, presented on a "NET" basis, rounded to the nearest $5 million.
Merial 3Q `00 3Q `99 9 mos '00 9 mos '99 IVOMEC, HEARTGARD, other avermectins $ 150 $ 180 $ 405 $ 430 FRONTLINE 90 110 275 270 Biologicals 80 85 240 250 Other Animal Health 50 55 150 165 Poultry Genetics 55 50 165 175 ------ ------ ------ ------ TOTAL MERIAL SALES $ 425 $ 480 $1,235 $1,290
PM-MSD 3Q `00 3Q `99 9 mos '00 9 mos '99 HEPATITIS VACCINES $ 35 $ 40 $110 $120 VIRAL VACCINES 10 15 35 50 Other Vaccines 125 120 260 245 ---- ---- ---- ---- TOTAL PM-MSD SALES $170 $175 $405 $415
TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (in millions)
2000 1999 % Chg FIRST QUARTER 99 94 5% SECOND QUARTER 98 91 8% THIRD QUARTER 120 90 33% --- --- -- YEAR TO DATE 317 275 15%